US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

The Oncology Institute

6.53

+0.16002.51%

Post-market: 6.530.00000.00%19:40 EDT

Volume:1.39M

Turnover:9.06M

Market Cap:665.51M

PE:-21.46

High:6.69

Open:6.42

Low:6.38

Close:6.37

52wk High:7.05

52wk Low:2.32

Shares:101.92M

Float Shares:88.60M

Volume Ratio:1.39

T/O Rate:1.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3042

EPS(LYR):-0.5445

ROE:--

ROA:-9.65%

PB:-26.71

PE(LYR):-11.99

Loading ...

Overview Company News Filings

Starling Oncology Forecasts Fy2026 Revenue of $650-670 Million

Starling Oncology - Brad Hively no Longer Serves as Vice Chairman or Committee Member Effective Immediately - SEC Filing

THOMSON REUTERS

Starling Oncology - Brad Hively Will not Stand for Re-Election to Starling Oncology Board at 2027 Annual Meeting - SEC Filing

THOMSON REUTERS

Starling Oncology Director Brad Hively to Step Down as Vice Chairman, not Seek Re-Election in 2027

Starling Oncology Director Brad Hively Reports Sale of 298,853 Common Shares Worth $1.95 Million

Starling Oncology Executives Join Wells Fargo Healthcare Conference Fireside Chat

Starling Oncology Enters USD 25 Million Revolving Credit Facility with Gemino Healthcare Finance

Starling Oncology - Credit Facility up to $25 Mln Secured - SEC Filing

THOMSON REUTERS

Starling Oncology 10% Owner Jorey Chernett Acquires 12,000 Shares Worth $78,480

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

B. Riley Adjusts Price Target on Starling Oncology to $11 From $8, Maintains Buy Rating

MT Newswires Live

Starling Oncology Shares Rise on Sales Outlook Lift

Starling Oncology Lifts FY 2026 Revenue Outlook to $650-$670 Million

Oncology Institute Q2 FY26 Net Loss Narrows 42.4% to $9.79 Million; Revenue Rises 34.6% to $161.28 Million

The Oncology Institute Q2 EPS $(0.08) Misses $(0.06) Estimate, Sales $161.282M Beat $155.193M Estimate

Benzinga Earnings

Starling Oncology Outlook FY Adjusted Ebitda USD 2-7 Million

THOMSON REUTERS

Starling Oncology Outlook FY Revenue USD 650-670 Million

THOMSON REUTERS

Starling Oncology Q2 EPS USD -0.08

THOMSON REUTERS

Starling Oncology Q2 Revenue USD 161.282 Million

THOMSON REUTERS

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/STLN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"STLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"STLN\",,,,,undefined,":{"symbol":"STLN","market":"US","secType":"STK","nameCN":"The Oncology Institute","latestPrice":6.53,"timestamp":1789588800000,"preClose":6.37,"halted":0,"volume":1388427,"hourTrading":{"tag":"盘后","latestPrice":6.53,"preClose":6.53,"latestTime":"19:40 EDT","volume":34457,"amount":225010.51563100002,"timestamp":1789602038702,"change":0,"changeRate":0,"amplitude":0.003063},"delay":0,"changeRate":0.02511773940345371,"floatShares":88601299,"shares":101916100,"eps":-0.304237,"marketStatus":"Post-Mkt","change":0.16,"latestTime":"09-16 19:53:21 EDT","open":6.42,"high":6.69,"low":6.375,"amount":9055776.853426801,"amplitude":0.049451,"askPrice":6.54,"askSize":3,"bidPrice":6.52,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-0.304237,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":6.37,"preHourTrading":{"tag":"盘前","latestPrice":6.15,"preClose":6.37,"latestTime":"08:55 EDT","volume":267,"amount":1712.5829628000001,"timestamp":1789563357611,"change":-0.22,"changeRate":-0.034537,"amplitude":0.047096},"postHourTrading":{"tag":"盘后","latestPrice":6.53,"preClose":6.53,"latestTime":"19:40 EDT","volume":34457,"amount":225010.51563100002,"timestamp":1789602038702,"change":0,"changeRate":0,"amplitude":0.003063},"volumeRatio":1.389657,"impliedVol":1.1867,"impliedVolPercentile":0.871},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"STLN\",,,,,undefined,":{"symbol":"STLN","floatShares":88601299,"roa":"-9.65%","roe":"--","lyrEps":-0.544488,"volumeRatio":1.389657,"shares":101916100,"dividePrice":0,"high":6.69,"amplitude":0.049451,"preClose":6.37,"low":6.375,"week52Low":2.32,"pbRate":"-26.71","psRate":"1.13","week52High":7.05,"institutionHeld":0,"latestPrice":6.53,"committee":0.5,"eps":-0.304237,"divideRate":0,"volume":1388427,"delay":0,"ttmEps":-0.304237,"open":6.42,"prevYearClose":3.56,"prevWeekClose":6.17,"prevMonthClose":5.91,"prevQuarterClose":5.43,"fiveDayClose":6.29,"twentyDayClose":6.4,"sixtyDayClose":5.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/STLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"STLN","fiscalQuarterEnding":"2026/06","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.08},{"date":"2026-05-06","symbol":"STLN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1778097600000,"name":null,"time":"Post-Mkt","dateTimestamp":1778040000000,"actualEps":null},{"market":"US","date":"2026-03-12","symbol":"STLN","fiscalQuarterEnding":"2025/12","expectedEps":-0.08,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-11-13","symbol":"STLN","fiscalQuarterEnding":"2025/09","expectedEps":-0.12,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-08-13","symbol":"STLN","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"STLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"STLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/STLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"STLN","date":"2026-09-15","current":-21.134839,"percent":0.103448,"low":-18.702266,"twenty":-18.022694,"median":-17.494762,"eighty":-16.674783,"high":-11.557791,"avg":-16.89093,"sd":1.922712,"marketCap":664493069},"quantilePoints":[{"date":"2026-08-07","current":-13.746861,"twenty":-12.626432,"median":-11.833524,"eighty":-11.695657,"marketCap":498914835},{"date":"2026-08-14","current":-17.579006,"twenty":-17.646402,"median":-17.298192,"eighty":-11.842715,"marketCap":637994879},{"date":"2026-08-21","current":-18.365288,"twenty":-18.045159,"median":-17.64921,"eighty":-12.999908,"marketCap":666531392},{"date":"2026-08-28","current":-17.803658,"twenty":-18.129404,"median":-17.719414,"eighty":-15.827113,"marketCap":646148169},{"date":"2026-09-04","current":-16.764643,"twenty":-18.045159,"median":-17.487741,"eighty":-16.646701,"marketCap":608439206},{"date":"2026-09-11","current":-17.410518,"twenty":-17.988996,"median":-17.494762,"eighty":-16.66355,"marketCap":631879913},{"date":"2026-09-15","current":-18.309125,"twenty":-18.022694,"median":-17.494762,"eighty":-16.674783,"marketCap":664493069}],"updateTime":1789579444842},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"STLN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666582310","title":"Starling Oncology Forecasts Fy2026 Revenue of $650-670 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582310","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582310?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:38","pubTimestamp":1788950292,"startTime":"0","endTime":"0","summary":"Starling Oncology forecasts FY2026 revenue of $650-670 millionStarling Oncology forecast FY26 revenue of USD 650-670 million, based on guidance reiterated in its Aug. 6, 2026 2Q26 release.Adjusted EBI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL1fb2rf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818219","title":"Starling Oncology - Brad Hively no Longer Serves as Vice Chairman or Committee Member Effective Immediately - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818219","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818219?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:06","pubTimestamp":1788343574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T17H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664182148","title":"Starling Oncology - Brad Hively Will not Stand for Re-Election to Starling Oncology Board at 2027 Annual Meeting - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664182148","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664182148?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:06","pubTimestamp":1788343574,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T17H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818291","title":"Starling Oncology Director Brad Hively to Step Down as Vice Chairman, not Seek Re-Election in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818291","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818291?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:05","pubTimestamp":1788343526,"startTime":"0","endTime":"0","summary":"Starling Oncology director Brad Hively to step down as vice chairman, not seek re-election in 2027Starling Oncology director Brad Hively will not stand for re-election at the 2027 annual stockholders ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL98mpdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4185","STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209372","title":"Starling Oncology Director Brad Hively Reports Sale of 298,853 Common Shares Worth $1.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209372","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209372?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:11","pubTimestamp":1787605916,"startTime":"0","endTime":"0","summary":"Starling Oncology director Brad Hively reports sale of 298,853 common shares worth $1.95 millionStarling Oncology director Brad Hively sold 298,853 common shares on Aug. 21, 2026 at a weighted average","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4g4JlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Starling Oncology Director Brad Hively Reports Sale of 298,853 Common Shares Worth $1.95 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279738","title":"Starling Oncology Executives Join Wells Fargo Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279738","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279738?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:02","pubTimestamp":1787576543,"startTime":"0","endTime":"0","summary":"Starling Oncology executives join Wells Fargo Healthcare Conference fireside chatStarling Oncology executives will attend the Wells Fargo Healthcare Conference in Boston on Sept. 8, 2026.CEO Daniel Vi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL2PZT0w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","BCDF","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","NDAQ","BK4585","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","BK4588","BK4185","STLN","SG9999014039.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290251","title":"Starling Oncology Enters USD 25 Million Revolving Credit Facility with Gemino Healthcare Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290251","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290251?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:29","pubTimestamp":1787347760,"startTime":"0","endTime":"0","summary":"Starling Oncology enters USD 25 million revolving credit facility with Gemino Healthcare FinanceStarling Oncology subsidiary SOM entered a revolving loan agreement with Gemino Healthcare Finance’s SLR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL2K0Bql:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN","BK4185","SLRC","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290401","title":"Starling Oncology - Credit Facility up to $25 Mln Secured - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290401?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:26","pubTimestamp":1787347585,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0Y3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4185","STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660414433","title":"Starling Oncology 10% Owner Jorey Chernett Acquires 12,000 Shares Worth $78,480","url":"https://stock-news.laohu8.com/highlight/detail?id=2660414433","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660414433?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:13","pubTimestamp":1786976026,"startTime":"0","endTime":"0","summary":"Starling Oncology 10% owner Jorey Chernett acquires 12,000 shares worth $78,480Starling Oncology 10% owner Jorey Chernett lifted his direct common-stock stake to 10,660,858 shares via a 12,000-share p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8ZKNvp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Starling Oncology 10% Owner Jorey Chernett Acquires 12,000 Shares Worth $78,480","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4185","STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660909487","title":"Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2660909487","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660909487?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflowCERRITOS, Calif., Aug.  17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346055/0/en/starling-oncology-launches-starling-nexus-a-technology-platform-built-to-optimize-oncology-provider-engagement-and-accelerate-high-quality-care-at-scale.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","STLN","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657410956","title":"B. Riley Adjusts Price Target on Starling Oncology to $11 From $8, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657410956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657410956?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:09","pubTimestamp":1786111771,"startTime":"0","endTime":"0","summary":"Starling Oncology (STLN) has an average rating of buy and mean price target of $9, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657966648","title":"Starling Oncology Shares Rise on Sales Outlook Lift","url":"https://stock-news.laohu8.com/highlight/detail?id=2657966648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657966648?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:31","pubTimestamp":1786102260,"startTime":"0","endTime":"0","summary":"Starling Oncology shares gained after the company raised its sales outlook.The stock climbed 27% to $6.36 in pre-market trading Friday. Starling started trading publicly earlier this week.The community cancer care company said it now expects annual revenue to be $650 million to $670 million, up from prior guidance of $630 million to $650 million. It also raised its gross profit outlook.The raise came as Starling said second-quarter revenue jumped 35% to $161.3 million. That was ahead of Wall Street's estimate of $155.3 million.The company narrowed its loss to $9.8 million, or 8 cents a share, from $17 million, or 15 cents a share. Analysts polled by FactSet were expecting a loss of 6 cents a share.Starling signed its first delegated contracts outside of Florida, in Nevada and Oregon, and reached an exclusivity agreement with one of its largest partners across California.Those deals are expected to drive capitated revenue growth going forward, Chief Executive Daniel Virnich said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666495","title":"Starling Oncology Lifts FY 2026 Revenue Outlook to $650-$670 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666495","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:50","pubTimestamp":1786053001,"startTime":"0","endTime":"0","summary":"Starling Oncology lifts FY 2026 revenue outlook to $650-$670 millionThe Oncology Institute raised full-year 2026 revenue guidance to $650-$670 million from $630-$650 million.Gross profit forecast incr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLDtqP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666616","title":"Oncology Institute Q2 FY26 Net Loss Narrows 42.4% to $9.79 Million; Revenue Rises 34.6% to $161.28 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666616","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666616?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:46","pubTimestamp":1786052772,"startTime":"0","endTime":"0","summary":"Oncology Institute Q2 FY26 net loss narrows 42.4% to $9.79 million; revenue rises 34.6% to $161.28 millionThe Oncology Institute posted a GAAP net loss of $9.79 million for the quarter ended June 30, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6sPRmS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668326","title":"The Oncology Institute Q2 EPS $(0.08) Misses $(0.06) Estimate, Sales $161.282M Beat $155.193M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668326","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668326?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:28","pubTimestamp":1786051737,"startTime":"0","endTime":"0","summary":"The Oncology Institute (NASDAQ:TOI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61025716/oncology-institute-q2-eps-0-08-misses-0-06-estimate-sales-161-282m-beat-155-193m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"The Oncology Institute Q2 EPS $(0.08) Misses $(0.06) Estimate, Sales $161.282M Beat $155.193M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657849666","title":"Starling Oncology Outlook FY Adjusted Ebitda USD 2-7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657849666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657849666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXDNWJPG:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666825","title":"Starling Oncology Outlook FY Revenue USD 650-670 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666825?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXDNWJPG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570096","title":"Starling Oncology Q2 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570096?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047288,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXDNWJPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657166684","title":"Starling Oncology Q2 Revenue USD 161.282 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657166684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657166684?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXDNWJPG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661455","title":"Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661455","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661455?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"CERRITOS, Calif., Aug.  06, 2026  (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340785/0/en/Starling-Oncology-Reports-Second-Quarter-2026-Financial-Results-and-Updates-Full-Year-2026-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLR","BK4149","STLN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}